ImmunoGen to raise $84 million, adding own pipeline to Roche-licensed compounds
This article was originally published in Scrip
Executive Summary
ImmunoGen, which is focused on antibody-based anticancer products, priced a secondary public offering of seven million shares on 20 May at $12 per share, for proceeds of about $84 million. The offer price is about a 6% discount to the share price on 19 May.